Genmab A/S (Nasdaq: GMAB) has announced the acquisition of ProfoundBio, Inc., a clinical-stage company specializing in advanced antibody-drug conjugates (ADCs) for cancer treatment. The all-cash transaction, valued at $1.8 billion, is set to enhance Genmab’s clinical pipeline and expand its proprietary technology platforms. ProfoundBio, known for its innovative ADC technologies targeting ovarian cancer and other…